Skip to main content
. 2016 May 21;7(25):38467–38486. doi: 10.18632/oncotarget.9542

Figure 1. Antitumor and antiangiogenic effects of sunitinib in CAKI-1 RCC xenografts.

Figure 1

(A) Time to tumor progression (TTP) using Kaplan Meier estimate from 131 mice TTP data. (B) Relative tumor volume according to T0. Data are pooled from 15, 46 and 67 animals per group, respectively. Bars indicate the mean ± SEM. (C) Representative tumors from the placebo, responder, and progressive groups of vessel number, necrosis, and hypoxia detected by CD31, HE, and CA9 staining, respectively. The dashed region indicated the necrotic (N) area. Bars, 100 μm. (Below) Quantitative analysis of CD31, HE, and CA9 staining. Data are pooled from 5 animals per group. Bars indicate the mean ± SEM. (B and C) P-values were calculated using unpaired Student's t tests: **P < 0.01, ***P < 0.001.